Provenge vs. abiraterone? Who will win?













Ab is looking very good. J&J has deeper pockets, knows how to launch a product and support it. The problem I see here is the patient population that is targeted. For the most part, they will have wide spread metastatic bone disease by the time these drugs are considered. Performance status and quality of life issues will have to be considered on top of the heavy financial burden of Pro. Once Ab is out on the market, Pro will be used only on a select few who don't have to worry about $$$$$.